IGC Pharma Announces Promising Preclinical Results for TGR-63, a Dual-Acting Alzheimer's Drug Targeting Beta-Amyloid and Tau Pathology
Reuters
Sep 24
<a href="https://laohu8.com/S/IGC">IGC Pharma</a> Announces Promising Preclinical Results for TGR-63, a Dual-Acting Alzheimer's Drug Targeting Beta-Amyloid and Tau Pathology
IGC Pharma Inc. (NYSE American: IGC) has announced new preclinical data on TGR-63, its investigational small-molecule candidate for Alzheimer's disease. The results demonstrate that TGR-63 inhibits both beta-amyloid and tau protein aggregation, addressing two key pathological features of Alzheimer's. In vitro assays showed that TGR-63 suppresses tau fibril formation at micromolar concentrations, and previous findings indicated its effectiveness in disrupting beta-amyloid plaque aggregation. Serum stability studies confirmed that TGR-63 maintains its structural integrity under physiological conditions and remains detectable in serum samples up to 24 hours post-administration. These preclinical findings have been presented by the company, and further development of TGR-63 is planned to advance it as a potential disease-modifying therapy for Alzheimer's disease.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IGC Pharma Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1077432) on September 24, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.